{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:25Z","timestamp":1790996665065,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40263-020-00782-w","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T13:47:08Z","timestamp":1613310428000},"page":"137-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations"],"prefix":"10.1007","volume":"35","author":[{"given":"Sandeep","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S. C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristide","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Soileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"issue":"21 Suppl. 4","key":"782_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl. 4):S1-136.","journal-title":"Neurology."},{"issue":"3","key":"782_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1756285616681280","volume":"10","author":"J Virhammar","year":"2017","unstructured":"Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson\u2019s disease: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(3):171\u201387.","journal-title":"Ther Adv Neurol Disord."},{"issue":"9","key":"782_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","volume":"16","author":"AH Schapira","year":"2009","unstructured":"Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson\u2019s disease. Eur J Neurol. 2009;16(9):982\u20139.","journal-title":"Eur J Neurol."},{"issue":"7","key":"782_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci."},{"issue":"3 Suppl.","key":"782_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ncl.2013.04.013","volume":"31","author":"VW Sung","year":"2013","unstructured":"Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson\u2019s disease: expanding the view of Parkinson\u2019s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013;31(3 Suppl.):S1-16.","journal-title":"Neurol Clin."},{"key":"782_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13\u201320.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"782_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, GLORIA study investigators and coordinators. Poewe W Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"8","key":"782_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","volume":"21","author":"M Buongiorno","year":"2015","unstructured":"Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, et al. Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21(8):871\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"782_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500\u20139.","journal-title":"Mov Disord."},{"issue":"3","key":"782_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.parkreldis.2012.11.020","volume":"19","author":"HH Fernandez","year":"2013","unstructured":"Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339\u201345.","journal-title":"Parkinsonism Relat Disord."},{"key":"782_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","volume":"37","author":"A Juhasz","year":"2017","unstructured":"Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A, et al. Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson\u2019s disease: an open-label study. Parkinsonism Relat Disord. 2017;37:79\u201386.","journal-title":"Parkinsonism Relat Disord."},{"issue":"11","key":"782_CR12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10072-016-2664-0","volume":"37","author":"L Lopiano","year":"2016","unstructured":"Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, et al. Motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Neurol Sci. 2016;37(11):1785\u201392.","journal-title":"Neurol Sci."},{"issue":"9","key":"782_CR13","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","volume":"266","author":"L Lopiano","year":"2019","unstructured":"Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, et al. Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol. 2019;266(9):2164\u201376.","journal-title":"J Neurol."},{"issue":"4","key":"782_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136.","journal-title":"Mov Disord."},{"issue":"2","key":"782_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol."},{"issue":"1","key":"782_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis. 2015;5(1):165\u201374.","journal-title":"J Parkinsons Dis."},{"issue":"6","key":"782_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mdc3.12526","volume":"4","author":"DG Standaert","year":"2017","unstructured":"Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, et al. Effect of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson\u2019s disease. Mov Disord Clin Pract. 2017;4(6):829\u201337.","journal-title":"Mov Disord Clin Pract."},{"issue":"4","key":"782_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nmt-2016-0021","volume":"6","author":"F Valldeoriola","year":"2016","unstructured":"Valldeoriola F, Grandas F, Santos-Garcia D, Regidor I, Catalan MJ, Arbelo JM, et al. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson\u2019s disease. Neurodegener Dis Manag. 2016;6(4):289\u201398.","journal-title":"Neurodegener Dis Manag."},{"issue":"3","key":"782_CR19","first-page":"147","volume":"27","author":"G Abbruzzese","year":"2012","unstructured":"Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa\/carbidopa in advanced Parkinson\u2019s disease: efficacy, safety and patient selection. Funct Neurol. 2012;27(3):147\u201354.","journal-title":"Funct Neurol."},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fneur.2018.00620","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L, Li J, Chen J. Levodopa-carbidopa intestinal gel in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol. 2018;9:620.","journal-title":"Front Neurol."},{"issue":"5","key":"782_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-016-0336-5","volume":"30","author":"K Wirdefeldt","year":"2016","unstructured":"Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson\u2019s disease: a systematic review. CNS Drugs. 2016;30(5):381\u2013404.","journal-title":"CNS Drugs"},{"issue":"4","key":"782_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/ene.13847","volume":"26","author":"KR Chaudhuri","year":"2019","unstructured":"Chaudhuri KR, Antonini A, Robieson WZ, Sanchez-Solino O, Bergmann L, Poewe W, et al. Burden of non-motor symptoms in Parkinson\u2019s disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. Eur J Neurol. 2019;26(4):581-e43.","journal-title":"Eur J Neurol."},{"issue":"6","key":"782_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00415-017-8491-2","volume":"264","author":"M Zibetti","year":"2017","unstructured":"Zibetti M, Romagnolo A, Merola A, Priano L, Montanaro E, Angrisano S, et al. A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion. J Neurol. 2017;264(6):1085\u201390.","journal-title":"J Neurol."},{"key":"782_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-018-0070-4","volume":"4","author":"B Cruse","year":"2018","unstructured":"Cruse B, Morales-Briceno H, Chang FCF, Mahant N, Ha AD, Kim SD, et al. 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson\u2019s disease. NPJ Parkinsons Dis. 2018;4:34.","journal-title":"NPJ Parkinsons Dis."},{"issue":"9","key":"782_CR25","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000183146.78892.3f","volume":"65","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology. 2005;65(9):1506\u20137.","journal-title":"Neurology."},{"issue":"6","key":"782_CR26","first-page":"A4155","volume":"57","author":"M Karlsborg","year":"2010","unstructured":"Karlsborg M, Korbo L, Regeur L, Glad A. Duodopa pump treatment in patients with advanced Parkinson\u2019s disease. Dan Med Bull. 2010;57(6):A4155.","journal-title":"Dan Med Bull."},{"issue":"8","key":"782_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.parkreldis.2012.04.010","volume":"18","author":"K Busk","year":"2012","unstructured":"Busk K, Nyholm D. Long-term 24-h levodopa\/carbidopa gel infusion in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(8):1000\u20131.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"782_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.parkreldis.2014.12.019","volume":"21","author":"C Chang","year":"2015","unstructured":"Chang C, Tsui DS, Mahant N, Wolfe N, Kim SD, Ha AD, et al. 24 h Levodopa-carbidopa intestinal gel may reduce falls and \u201cunresponsive\u201d freezing of gait in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(3):317\u201320.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"782_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/mds.26564","volume":"31","author":"L Ricciardi","year":"2016","unstructured":"Ricciardi L, Bove F, Espay KJ, Lena F, Modugno N, Poon YY, et al. 24-Hour infusion of levodopa\/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson\u2019s disease. Mov Disord. 2016;31(4):597\u20138.","journal-title":"Mov Disord."},{"issue":"11","key":"782_CR30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/mds.27883","volume":"34","author":"H Morales-Brice\u00f1o","year":"2019","unstructured":"Morales-Brice\u00f1o H, Mahant N, Ha AD, et al. Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson\u2019s disease. Mov Disord. 2019;34(11):1747\u20138.","journal-title":"Mov Disord."},{"issue":"4","key":"782_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3233\/JPD-202114","volume":"10","author":"D Nyholm","year":"2020","unstructured":"Nyholm D, Adnan M, Senek M. Real-life use of levodopa\/carbidopa intestinal gel in Parkinson\u2019s disease according to analysis of pump data. J Parkinsons Dis. 2020;10(4):1529\u201334.","journal-title":"J Parkinsons Dis."},{"issue":"4","key":"782_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/mdc3.12630","volume":"5","author":"M Burack","year":"2018","unstructured":"Burack M, Aldred J, Zadikoff C, Vanagunas A, Klos K, Bilir B, et al. Implementing levodopa-carbidopa intestinal gel for Parkinson disease: insights from US practitioners. Mov Disord Clin Pract. 2018;5(4):383\u201393.","journal-title":"Mov Disord Clin Pract."},{"issue":"2","key":"782_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00415-018-8936-2","volume":"266","author":"JA Vizcarra","year":"2019","unstructured":"Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, et al. Subthalamic deep brain stimulation and levodopa in Parkinson\u2019s disease: a meta-analysis of combined effects. J Neurol. 2019;266(2):289\u201397.","journal-title":"J Neurol."},{"issue":"5","key":"782_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/ene.13895","volume":"26","author":"F Stocchi","year":"2019","unstructured":"Stocchi F, Coletti C, Bonassi S, Radicati FG, Vacca L. Early-morning OFF and levodopa dose failures in patients with Parkinson\u2019s disease attending a routine clinical appointment using Time-to-ON Questionnaire. Eur J Neurol. 2019;26(5):821\u20136.","journal-title":"Eur J Neurol."},{"issue":"4","key":"782_CR35","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mds.23524","volume":"26","author":"A Merola","year":"2011","unstructured":"Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson\u2019s disease. Mov Disord. 2011;26(4):664\u201370.","journal-title":"Mov Disord."},{"issue":"2","key":"782_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ene.12309","volume":"21","author":"M Zibetti","year":"2014","unstructured":"Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, et al. Levodopa\/carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: a 7-year experience. Eur J Neurol. 2014;21(2):312\u20138.","journal-title":"Eur J Neurol."},{"issue":"1","key":"782_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-012-6597-0","volume":"260","author":"M Zibetti","year":"2013","unstructured":"Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Long-term duodenal levodopa infusion in Parkinson\u2019s disease: a 3-year motor and cognitive follow-up study. J Neurol. 2013;260(1):105\u201314.","journal-title":"J Neurol."},{"issue":"5","key":"782_CR38","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mds.26970","volume":"32","author":"A Merola","year":"2017","unstructured":"Merola A, Romagnolo A, Comi C, Rosso M, Artusi CA, Zibetti M, et al. Prevalence and burden of dysautonomia in advanced Parkinson\u2019s disease. Mov Disord. 2017;32(5):796\u20137.","journal-title":"Mov Disord."},{"issue":"16","key":"782_CR39","doi-asserted-by":"publisher","first-page":"e1526","DOI":"10.1212\/WNL.0000000000008314","volume":"93","author":"YH Hiorth","year":"2019","unstructured":"Hiorth YH, Pedersen KF, Dalen I, Tysnes OB, Alves G. Orthostatic hypotension in Parkinson disease: a 7-year prospective population-based study. Neurology. 2019;93(16):e1526-34.","journal-title":"Neurology."},{"issue":"8","key":"782_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.parkreldis.2014.04.007","volume":"20","author":"C Noack","year":"2014","unstructured":"Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(8):815\u20138.","journal-title":"Parkinsonism Relat Disord."},{"issue":"11","key":"782_CR41","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/mds.21068","volume":"21","author":"CG Bachmann","year":"2006","unstructured":"Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson\u2019s disease. Mov Disord. 2006;21(11):1824\u201330.","journal-title":"Mov Disord."},{"issue":"8","key":"782_CR42","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1468-1331.2009.02617.x","volume":"16","author":"CG Bachmann","year":"2009","unstructured":"Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson\u2019s disease and dyskinesias. Eur J Neurol. 2009;16(8):895\u2013901.","journal-title":"Eur J Neurol."},{"issue":"3","key":"782_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/ene.13844","volume":"26","author":"M Fabbri","year":"2019","unstructured":"Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, et al. Levodopa\/carbidopa intestinal gel infusion and weight loss in Parkinson\u2019s disease. Eur J Neurol. 2019;26(3):490\u20136.","journal-title":"Eur J Neurol."},{"issue":"3","key":"782_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ene.12846","volume":"23","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016;23(3):501\u20139.","journal-title":"Eur J Neurol."},{"issue":"2","key":"782_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract. 2019;6(2):96\u2013103.","journal-title":"Mov Disord Clin Pract."},{"issue":"12","key":"782_CR46","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1111\/ene.14047","volume":"26","author":"D Pinter","year":"2019","unstructured":"Pinter D, Deli G, Juhasz A, Pal E, Janszky J, Kovacs N. Long-term successful treatment of chronic inflammatory demyelinating polyneuropathy-like polyneuropathy induced by levodopa-carbidopa intestinal gel with intravenous immunoglobulin. Eur J Neurol. 2019;26(12):e96-7.","journal-title":"Eur J Neurol."},{"issue":"6","key":"782_CR47","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","volume":"265","author":"MJ Catalan","year":"2018","unstructured":"Catalan MJ, Molina-Arjona JA, Mir P, Cubo E, Arbelo JM, Martinez-Martin P, et al. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. J Neurol. 2018;265(6):1279\u201387.","journal-title":"J Neurol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00782-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00782-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00782-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T08:08:28Z","timestamp":1674979708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00782-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00782-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"5 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding of the medical writing support for the development of this manuscript was provided by AbbVie Inc. The authors received no direct compensation for their efforts. AbbVie had the opportunity to review the final manuscript, but manuscript content was solely at the discretion of the authors and reflects the opinions of the authors. The open access fee was paid by AbbVie Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sandeep Thakkar has received funding\/grant support from Hoag Memorial Hospital Presbyterian as medical director for the Movement Disorders Program and honoraria for consultancy from Teva, AbbVie, Medtronic, Adamas, Amneal, and Neurocrine. Victor Fung receives a salary from NSW Health and has received unrestricted research grants from the Michael J. Fox Foundation, AbbVie, and Merz. He has served on advisory boards and\/or has received travel grants from AbbVie, Allergan, Cavion, Ipsen, Merz, Praxis, Segirus, Stada, Teva, and UCB, and royalties from Health Press, Ltd. Aristide Merola has received funding\/grant support from the National Institutes of Health (KL2 TR001426), Lundbeck, and Abbott and honoraria for consultancy from Lundbeck, AbbVie, Abbott, and Theravance. Meredith Rollins has received consultant compensation and honoraria from AbbVie. Michael Soileau has received consultant compensation from AbbVie, Medtronic, and Sunovion, and honoraria from AbbVie, Acorda, Amneal, Lundbeck, Merz, and Teva. Norbert Kov\u00e1cs has received funding\/grant support from the Hungarian National Research, Development and Innovation Office, National Excellence Program, University of P\u00e9cs, and Medtronic, and honoraria for consultancy from UCB, AbbVie, Abbott, Boston Scientific, Medtronic, KRKA, Teva, Boehringer Ingelheim, and GSK Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"ST, VSCF, and NK participated in the conception of the research project. ST, VSCF, AM, MR, MJS, and NK participated in the organization and execution of the project, as well as drafting, critically reviewing, and approving the manuscript for submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}